Avandia tablets
Media playback is unsupported on your device

Avandia drug to lower GlaxoSmithKline profits

GlaxoSmithKline is expected to be hit hard by multi-billion dollar legal charges relating to its controversial diabetes drug Avandia.

The pharmaceutical giant is to announce its full year results with shares in the company at a five-month low, and investors expecting to see profits almost halved.

Jon Bithrey reports.

  • 03 Feb 2011